AI brief of an SEC Form 8-K · Aflac (AFL)

Aflac Q1 net earnings fall to $29 million on $963 million investment loss

Mixed Impact 4 of 5 earnings Written later

Aflac reported first-quarter 2025 net earnings of $29 million, or $0.05 per diluted share, down from $1.9 billion, or $3.25 per diluted share, a year earlier. The drop was driven by net investment losses of $963 million, while adjusted earnings fell 5.7% to $906 million and adjusted earnings per diluted share were flat at $1.66. Shareholders also received a second-quarter dividend of $0.58 per share and the company repurchased $900 million of its shares during the quarter.

Key points

  • Total revenues were $3.4 billion, compared with $5.4 billion a year earlier, mainly due to net investment losses of $963 million versus net investment gains of $951 million in Q1 2024.
  • Adjusted earnings were $906 million, compared with $961 million in Q1 2024, a decrease of 5.7%; adjusted earnings per diluted share were $1.66, flat year over year.
  • Aflac declared a second-quarter dividend of $0.58 per share, payable June 2, 2025, to shareholders of record on May 21, 2025.
  • The company repurchased 8.5 million common shares for $900 million in the first quarter and had 38.8 million shares remaining under its repurchase authorization at the end of March 2025.

The filing

CompanyAflac (AFL)
Form8-K, current report
Filed with the SECApr 30, 2025, 4:43 PM ET
Accession number0000004977-25-000067

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.